中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

非酒精性脂肪性肝病代谢组学研究进展

栾雨婷 黄钟鸣 沈文娟 哈明昊 顼志兵

引用本文:
Citation:

非酒精性脂肪性肝病代谢组学研究进展

DOI: 10.3969/j.issn.1001-5256.2021.04.047
基金项目: 

上海中医药大学附属第七人民医院人才培养计划 (XX2019-17)

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:栾雨婷负责撰写修改论文;黄钟鸣、沈文娟、哈明昊负责参与文献的收集、整理;顼志兵负责拟定写作思路,指导撰写文章并最后定稿。
详细信息
    作者简介:

    栾雨婷(1990—),女,主要从事慢性肝病的基础与临床研究

    通信作者:

    顼志兵,xzb6160@163.com

  • 中图分类号: R575.5

Research advances in metabolomics in nonalcoholic fatty liver disease

  • 摘要: 非酒精性脂肪性肝病(NAFLD)发病率逐渐升高,已成为我国第一大慢性肝病的首要原因。目前对NAFLD的发病机制并未完全阐明且无特效药物。从发病机制、无创诊断、药物作用与疗效角度出发,介绍了以机体内源性小分子代谢物为研究对象的代谢组学在NAFLD中的研究进展,为进一步探索NAFLD提供新的思路与方法。

     

  • [1] DIEHL AM, DAY C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med, 2017, 377(21): 2063-2072. DOI: 10.1056/NEJMra1503519.
    [2] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
    [3] LI J, ZOU B, YEO YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398. DOI: 10.1016/S2468-1253(19)30039-1.
    [4] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10. 3969/j. issn.1001-5256.2018.05.007

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007
    [5] ESTES C, RAZAVI H, LOOMBA R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease[J]. Hepatology, 2018, 67(1): 123-133. DOI: 10.1002/hep.29466.
    [6] ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
    [7] ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312.
    [8] XUE R, FAN JG. Brief introduction of an international expert consensus statement: A new definition of metabolic associated fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007.

    薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007.
    [9] NICHOLSON JK, LINDON JC, HOLMES E. 'Metabonomics': Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data[J]. Xenobiotica, 1999, 29(11): 1181-1189. DOI: 10.1080/004982599238047.
    [10] XU TR, LIU XY, XU GW. Advances of analytical methods for liquid chromatography-mass spectrometry-based metabolomics[J]. J Instrumental Analysis, 2020, 39(1): 10-18. DOI: 10.3969/j.issn.1004-4957.2020.01.002.

    徐天润, 刘心昱, 许国旺. 基于液相色谱-质谱联用技术的代谢组学分析方法研究进展[J]. 分析测试学报, 2020, 39(1): 10-18. DOI: 10.3969/j.issn.1004-4957.2020.01.002.
    [11] NASCIMBENI F, PAIS R, BELLENTANI S, et al. From NAFLD in clinical practice to answers from guidelines[J]. J Hepatol, 2013, 59(4): 859-871. DOI: 10.1016/j.jhep.2013.05.044.
    [12] DAY CP, JAMES OF. Steatohepatitis: A tale of two "hits"?[J]. Gastroenterology, 1998, 114(4): 842-845. DOI: 10.1016/s0016-5085(98)70599-2.
    [13] TILG H, MOSCHEN AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis[J]. Hepatology, 2010, 52(5): 1836-1846. DOI: 10.1002/hep.24001.
    [14] TILG H, ADOLPH TE, MOSCHEN AR. Multiple parallel hits hypothesis in NAFLD - revisited after a decade[J]. Hepatology, 2021, 73(2): 833-842. DOI: 10.1002/hep.31518.
    [15] CABRÉ N, LUCIANO-MATEO F, BAIGES-GAYÀ G, et al. Plasma metabolic alterations in patients with severe obesity and non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther, 2020, 51(3): 374-387. DOI: 10.1111/apt.15606.
    [16] ZHONG G, KIRKWOOD J, WON KJ, et al. Characterization of vitamin A metabolome in human livers with and without nonalcoholic fatty liver disease[J]. J Pharmacol Exp Ther, 2019, 370(1): 92-103. DOI: 10.1124/jpet.119.258517.
    [17] SHIH LM, TANG HY, LYNN KS, et al. Stable isotope-labeled lipidomics to unravel the heterogeneous development lipotoxicity[J]. Molecules, 2018, 23(11): 2862. DOI: 10.3390/molecules23112862.
    [18] European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol, 2015, 63(1): 237-264. DOI: 10.1016/j.jhep.2015.04.006.
    [19] MARENGO A, JOUNESS RI, BUGIANESI E. Progression and natural history of nonalcoholic fatty liver disease in adults[J]. Clin Liver Dis, 2016, 20(2): 313-324. DOI: 10.1016/j.cld.2015.10.010.
    [20] ZENG J, FAN JG. Clinical significance of renaming nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1205-1207. DOI: 10.3969/j.issn.1001-5256.2020.06.002.

    曾静, 范建高. 非酒精性脂肪性肝病更名的临床意义[J]. 临床肝胆病杂志, 2020, 36(6): 1205-1207. DOI: 10.3969/j.issn.1001-5256.2020.06.002.
    [21] MOOLLA A, de BOER J, PAVLOV D, et al. Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome[J]. Aliment Pharmacol Ther, 2020, 51(11): 1188-1197. DOI: 10.1111/apt.15710.
    [22] MAYO R, CRESPO J, MARTÍNEZ-ARRANZ I, et al. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts[J]. Hepatol Commun, 2018, 2(7): 807-820. DOI: 10.1002/hep4.1188.
    [23] YANG RX, HU CX, SUN WL, et al. Serum monounsaturated triacylglycerol predicts steatohepatitis in patients with non-alcoholic fatty liver disease and chronic hepatitis B[J]. Sci Rep, 2017, 7(1): 10517. DOI: 10.1038/s41598-017-11278-x.
    [24] HU WY, MA XH, LI XX, et al. Progress of potential drugs in non-alcohol fatty liver disease[J]. Chin J New Drugs, 2017, 26(14): 1661-1666. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ201714009.htm

    胡文义, 马晓慧, 李欣欣, 等. 非酒精性脂肪肝潜在药物研究进展[J]. 中国新药杂志, 2017, 26(14): 1661-1666. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ201714009.htm
    [25] DENG Y, PAN M, NIE H, et al. Lipidomic analysis of the protective effects of Shenling Baizhu San on non-alcoholic fatty liver disease in rats[J]. Molecules, 2019, 24(21): 3943. DOI: 10.3390/molecules24213943.
    [26] XU Y, HAN J, DONG J, et al. Metabolomics characterizes the effects and mechanisms of quercetin in nonalcoholic fatty liver disease development[J]. Int J Mol Sci, 2019, 20(5): 1220. DOI: 10.3390/ijms20051220.
    [27] KALAVALAPALLI S, BRIL F, GUINGAB J, et al. Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis[J]. J Endocrinol, 2019, 241(3): 293-305. DOI: 10.1530/JOE-19-0007.
    [28] TORQUATO P, GIUSEPPONI D, ALISI A, et al. Nutritional and lipidomics biomarkers of docosahexaenoic acid-based multivitamin therapy in pediatric NASH[J]. Sci Rep, 2019, 9(1): 2045. DOI: 10.1038/s41598-018-37209-y.
    [29] WU Y, LI L. Sample normalization methods in quantitative metabolomics[J]. J Chromatogr A, 2016, 1430: 80-95. DOI: 10.1016/j.chroma.2015.12.007.
    [30] YIN P, XU G. Current state-of-the-art of nontargeted metabolomics based on liquid chromatography-mass spectrometry with special emphasis in clinical applications[J]. J Chromatogr A, 2014, 1374: 1-13. DOI: 10.1016/j.chroma.2014.11.050.
    [31] GONZÁLEZ-DOMÍNGUEZ R, GONZÁLEZ-DOMÍNGUEZ Á, SAYAGO A, et al. Recommendations and best practices for standardizing the pre-analytical processing of blood and urine samples in metabolomics[J]. Metabolites, 2020, 10(6): 1220. DOI: 10.3390/metabo10060229.
    [32] MISRA BB. Data normalization strategies in metabolomics: Current challenges, approaches, and tools[J]. Eur J Mass Spectrom (Chichester), 2020, 26(3): 165-174. DOI: 10.1177/1469066720918446.
    [33] CHERNYAK OO, SENTSOVA TB, VOROZHKO IV, et al. Genomic, proteomic and metabolomic predictors of nonalcoholic fatty liver disease development in obese patients. Part I[J]. Vopr Pitan, 2015, 84(4): 18-24. http://europepmc.org/abstract/MED/26852528
    [34] MESNAGE R, RENNEY G, SÉRALINI GE, et al. Multiomics reveal non-alcoholic fatty liver disease in rats following chronic exposure to an ultra-low dose of Roundup herbicide[J]. Sci Rep, 2017, 7: 39328. DOI: 10.1038/srep39328.
    [35] DEL CHIERICO F, NOBILI V, VERNOCCHI P, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach[J]. Hepatology, 2017, 65(2): 451-464. DOI: 10.1002/hep.28572.
    [36] CARULLI L, ZANCA G, SCHEPIS F, et al. The OMICs window into nonalcoholic fatty liver disease (NAFLD)[J]. Metabolites, 2019, 9(2): 25. DOI: 10.3390/metabo9020025.
    [37] PIAZZOLLA VA, MANGIA A. Noninvasive diagnosis of NAFLD and NASH[J]. Cells, 2020, 9(4): 1005. DOI: 10.3390/cells9041005.
    [38] ZHANG W, SHI JP. A new model for prevention and treatment of MAFLD to promote whole process stratification management[J]. J Prac Hepatol, 2020, 23(5): 609-611. DOI: 10.3969/j.issn.1672-5069.2020.05.001.

    张伟, 施军平. 创建MAFLD防治新模式, 合力推进分层全程管理[J]. 实用肝脏病杂志, 2020, 23(5): 609-611. DOI: 10.3969/j.issn.1672-5069.2020.05.001.
  • 加载中
计量
  • 文章访问数:  655
  • HTML全文浏览量:  1241
  • PDF下载量:  113
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-11-06
  • 录用日期:  2020-12-17
  • 出版日期:  2021-04-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回